Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer

Cancer Investigation

Volumn 27, Issue 2, 2009, Pages 206-214

  Tang, Shou Ching ^a,b,c  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Anthracycline; Docetaxel; Early Breast cancer; Paclitaxel; Quality of life; Taxanes; Toxicity

Indexed keywords

CAPECITABINE; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; IXABEPILONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ALOPECIA; ANEMIA; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DYSPNEA; EARLY CANCER; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LACRIMATION DISORDER; LEUKEMIA; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; TAXOIDS; TUBULIN;

EID: 60849121122     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802178520     Document Type: Review

References (49)

1. Ferguson, T.; Wilcken, N.; Vagg, R.;, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007. Issue 4. Art. No.: CD004421. DOI: 10.1002/14651858.CD004421.pub2.
2. De Laurentiis, M.; Giuseppe, C.; D'Agostino, D.; et al. Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. J Clin Oncol 2008, 1(26):44-52.
3. Hortobagyi, G.N.; Holmes, F.A. Single-agent Paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996, 23(Suppl 1), 4-9.
4. Trudeau, M.E.; Eisenhauer, E.A.; Higgins, B.P.; et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996, 14, 422-428.
5. Seidman, A.D. Single-agent Paclitaxel in the treatment of breast cancer: phase I and II development. Semin Oncol 1999 Jun; 26(3 Suppl 8), 14-20.
6. Culine, S. Taxotere as second-line for metastatic breast cancer. Rev Med Interne 1999 Mar; 20(3), 277-280.
7. Seidman, A.D., Berry, D.; Cirrincione, C. et al. CALGB 9840: Phase III Study of weekly (W) Paclitaxel (P) via 1-hour (H) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004, 22(14S), 512.
8. Tabernero, J.; Climent, M.A. Lluch, A. et al. A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Annals Oncol 2004, 15(9), 1358-1365.
9. Cassier, P.A. Chabaud, S.; Trillet-Lenoir, V. et al. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer : results of the ERASME 3 study. Breast Cancer Res Treat 2007 Jul 5 [Epub ahead of print].
10. Kaufman, P.A. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Semin Oncol 1999, Jun; 26(3 Suppl 8), 39-46.
11. Nabholtz, J.M.; Tonkin, K.; Smylie, M.; et al. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol 1999 Feb; 26(1 Suppl 3), 10-6.
12. Henderson, I.C.; Berry, D.A. Demetri, G.D.; et al. Improved outcomes from adding sequential paclixaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21, 976-983.
13. Martin, M.; Pienkowski, T.; Mackey, J.; et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352, 2303-2313.
14. Trudeau, M.; Pagani, O. Epirubicin in combination with the taxanes. Semin Oncol 2001, Aug; 28(4 Suppl 12), 41-50.
15. Airoldi, M.; Cattel, L.; Pedani, F.; et al. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat 2001 Dec; 70(3), 185-95.
16. Salminen, E.; Syvanen, K.; Korpela, J.; et al. Docetaxel with epirubicin-investigations on cardiac safety. Anticancer Drugs 2003 Jan; 14(1), 73-77.
17. Rischin, D.; Smith, J.; Millward, M.; et al. A phase II trail of Paclitaxel and epirubicin in advanced breast cancer. Br J Cancer 2000, 83, 438-442.
18. Bonneterre, J.; Tubiana-Hulin, M.; Catimel, G. Paclitaxel, epirubicin and Cyclophosphamide Combination in First-line treatment on metastatic breast cancer: A dose escalation study. Oncology 2004, 66, 185-191. 0
19. Conte, P.F.; Baldini, E.; Gennari, A. Dose-finding study and pharmacokinetics of epirubicin and Paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clinl Oncol 1997, 15, 2510-2517.
20. Luck, H.J.; Thomassen, C.; Du Bois, A.; et al. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol 1997 Oct, 24(5 Suppl 17), S17-35-S17-39.
21. Roche, H.; Fumoleau, P.; Spielmann, M.; et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patient: The FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24, 5664-5671.
22. Hudis, C.; Citron, M.; and Berry, D.; et al. Five year follow-up if INT C9741: Dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 2005, 94, 39 (Supple; abstr 41).
23. Moebus, V.J.; Lueck, H.J.; Thomssen, C.; et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional schedule chemotherapy in high-risk breast cancer patients (> 4+ LN). Mature results of an AGO-trial. Breast Cancer Res Treat 2006, 100(suppl1), S20. Abstract 43.
24. Burnell, M.; Levine, M.; Chapman, J.A.; et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Res Treat 2006, 100(suppl1). Abstract 53.
25. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001 Mar 15, 344(11), 783-792.
26. Gianni, L.; Salvatorelli, E.; Minotti, G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007, 7(2), 67-71.
27. Ewer, M.S.; O'Shaughnessy, J.A. Cardiac toxicity of trastuzumab-related regimens in HER2 overexpressing breast cancer. Clin Breast Cancer 2007, Jun;7(8), 600-607.
28. Slamon, D.; Eiermann, W.; Robert, N.; et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Proceedings of the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas. 2006. Abstract 52.
29. Sparano, J.A.; Wang, M.; Martino, S.; et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N Engl J Med 2008, April: 358(16), 1663-1671.
30. Eiermann, W.; Pienkowski, T.; Crown, J.; et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res Treat 2005, 94, (Supple; abstr 1069).
31. Nabholtz, J.M.; Cantin, J.; Chang, J.; et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 2002 Oct;3(4), 268-275.
32. Martin, M.; Lluch, A.; Seguí, M. A.; et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006 Aug;17(8), 1205-1212.
33. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005 Nov 1; 23(31), 7794-7803.
34. Robert, N.; Ambro, S.; Krekow, L.; et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. Breast Cancer Res Treat 2005, 94, (Supple1;abstr 2073).
35. Low, J.A. Wedam, S.B. Lee, J. J.; et al. Phase II Clinical Trail of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer. J Clin Oncol 2005 April: 23(12), 2726-2734.
36. Thomas, E, Gomez, H.; Li, R.; et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol, 2007, 25, 5210-5217
37. Cardoso F., de Azambuja, E.; Lago, L.D. Current perspectives of epothilones in breast cancer. Eur J Cancer 2008 Jan 4.
38. Jones, S.; Holmes, F.; O'Shaughnessy, J.; Blum, J.; et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007, 106(Supple;abstr 12).
39. Hasegawa, S.; Miyoshi, Y.; Egawa, C.; et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003, 9(8), 2992-2997.
40. Paradiso, A.; Mangia, A.; Chiriatti, A.; et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol, 2005, 16 Suppl 4, iv14-iv9.
41. Seve, P.; Reiman, T.; Lai, R.; et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007, 60(1), 27-34.
42. Rouzier, R.; Rajan, R.; Wagner, P.; et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005, 102(23), 8315-8320.
43. Andre, F.; Hatzis, C.; Anderson, K.; et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13(7), 2061-2067.
44. Barlow, S.B.; Gonzalez-Garay, M.L.; Cabral, F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J Cell Sci 2002, 115(Pt 17), 3469-3478.
45. Bernard-Marty, C.; Treilleux, I.; Dumontet, C.; et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin. Breast Cancer 2002, 3(5), 341-345.
46. Salvatorelli, E.; Menna, P.; Cascegna, S.; et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J. Pharmacol Exp Ther 2006, Jul; 318(1), 424-433. Epub 2006 Apr 13.
47. Slamon, D.J.; Mackey, J.; Robert, N.; et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Proceedings of the 30th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas. 2007. Abstract 13.
48. Henry, N.L.; Hayes, D.F. Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. Oncol. 2007 Oct; 21(11), 1301-1309.
49. Tang, S. Molecular predictive markers of tubulin-targeting agents. Clinical Breast Cancer 2008, 8, suppl. 79-84.